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ABSTRACT
This pilot case-control study at a tertiary-care hospital over a four-month period was aimed at evaluating 
the possible usefulness of screening of TORCH (Toxoplasma gondii, rubella virus, cytomegalovirus, and Her-
pes simplex virus) in females with bad obstetric history. The study included 12 women with bad obstetric 
history and a similar number of matched controls with previous normal pregnancies. A serological evalu-
ation of TORCH infections was carried out by detecting IgG and IgM antibodies against these infections 
by ELISA test-kit. Statistical analysis was not done to compare the results relating to the two groups due to 
a small number of cases and controls included in the study. Ten (83.3%) of the 12 cases with bad obstetric 
history and two (16.7%) of the 12 healthy controls were serologically positive at least for one of the TORCH 
agents. The seropositivity rate in women with bad obstetric history was quite high compared to that in the 
normal healthy controls. The results suggest that a previous history of pregnancy wastage and the serologi-
cal evaluation of TORCH infections during current pregnancy must be considered while managing cases 
with bad obstetric history. 
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INTRODUCTION
Bad obstetric history (BOH) implies previous unfa-
vourable foetal outcome in terms of two or more 
consecutive spontaneous abortions, history of in-
trauterine foetal death, intrauterine growth retar-
dation, stillbirth, early neonatal death and/or con-
genital anomalies. Cause of BOH may be genetic, 
hormonal, abnormal maternal immune response, 
and maternal infection (1). Primary infections 
caused by TORCH—Toxoplasma gondii, rubella vi-
rus, cytomegalovirus (CMV), and Herpes simplex 
virus (HSV)—is the major cause of BOH (2). 
The prevalence of these infections varies from one 
geographical area to another (3). These maternal 
infections are initially unapparent or asympto-
matic and are, thus, difficult to diagnose on clini-
cal grounds (4,5). Therefore, diagnosis of acute 
TORCH infection in pregnant women is usually 
established by demonstration of seroconversion 
in paired sera or by demonstration of specific IgM 
antibodies (1). Enzyme-linked immunosorbent as-
say (ELISA) for IgM antibodies against these infec-
tions is highly sensitive and specific (6). The con-
ventional single serum assays do not make a clear 
distinction between a recent primary and chronic 
infection. The tendency of specific IgM to persist 
for a long time even at high levels has been veri-
fied in several studies (7,8). After its introduction in 
serodiagnosis of Toxoplasma-associated infections, 
the measurement of IgG avidity has proved to be a 
highly-useful procedure, especially in combination 
with conventional serological assays (9).
However, this pilot study was aimed at evaluating 
the possible usefulness of conventional screening 
of TORCH in females with BOH in eastern Nepal.
MATERIALS AND METHODS
Study setting and design 
This pilot case-control study was carried out over 
a four-month period at a tertiary referral hospital 
in Nepal.Kumari N et al. Screening of TORCH in women with bad obstetric history
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Twelve women with BOH and a similar number of 
matched controls (without any BOH and previous 
normal pregnancies) attending our antenatal clinic 
were included in the study. Cases were selected 
depending on a previous history of having 2-3 
pregnancy wastages, intrauterine deaths, preterm 
deliveries, intrauterine growth retardation, and un-
explained early neonatal deaths. 
Factors considered for selecting matched controls 
were age (±2 years), similar gravidity, same period of 
gestation in present pregnancy, and same number 
of livebirths opposed to bad obstetric complaints 
in the cases group. Detailed examinations and con-
ventional laboratory investigations were carried 
out in both the groups. After taking consent from 
each woman, 3 mL of venous blood was collected 
in a container with strict aseptic precautions. The 
serum, thus, obtained was used for serological eval-
uation of TORCH infections. TORCH IgG and IgM 
antibodies were detected from the serum by ELISA 
test-kit (Calbiotech Inc, Canada) following the in-
structions of the manufacturer. The kits for detec-
tion of antibodies were based on sandwich ELISA 
method. Absorbance was taken at wavelength of 
450 nm, and results were calculated according to   
the instructions. TORCH antibody index was calcu-
lated by dividing the value of each sample by cali-
brator values. The antibody index of 1.0 or greater 
was considered positive for antibodies.
The results of the two groups (cases and controls) 
were compared (Table 1). Statistical analysis was 
not done to compare the results relating to the two 
groups due to a small number of cases and controls 
included in the study.
Ethical approval
The Ethical Committee of the Institute granted 
ethical clearance to the study.
RESULTS
Different presentations of BOH cases and matched 
controls with their TORCH status are shown in Ta-
ble 1, and seropositivity of TORCH agents in the 
two groups is shown in Table 2. Five cases showed 
mixed seropositivity. Mixed seropositivity was not 
found in any of the controls. A maximum number 
of BOH cases was found in females aged 18-24 
years.
Ten (83.3%) of the 12 BOH cases and two (16.7%) 
of the 12 healthy controls were serologically posi-
tive at least for one of the TORCH agents. The sero-
positivity rate in women with BOH was quite high 
compared to that in the normal healthy controls.
In the BOH cases, the seropositivity for T. gondii was 
50%, rubella virus 50%, HSV-2 33.3%, and CMV 
8.3% whereas, in the control cases, the seropositiv-
ity for T. gondii was 16.7% only and that of the re-
maining ones was 0%.
DISCUSSION
To the best of our knowledge, baseline data on sero-
positivity in the local population are not available 
from any part of Nepal. In the present study, T. gon-
dii (50%), rubella virus (50%), HSV-2 (33.3%), and 
CMV (8.3%) were found in pregnant women with 
BOH. These data are very high compared to those 
available from the neighbouring country (India) 
(3,7). It might be due to the fact that the number 
of cases and controls included in the present study 
is very less, and, as such, it may not be reflect the 
true picture of TORCH infections. However, the 
difference between the two groups was quite sig-
nificant numerically.
Although IgG of the samples was determined, the 
interpretation is mainly based on the value of IgM 
as paired sera were not tested.
Further, the cost of the whole TORCH-panel test 
being very high, most general population of an un-
derdeveloped country, such as Nepal, cannot com-
fortably afford. By including vaccination against 
rubella virus (MMR vaccine) in the national im-
munization schedule, the incidence of congenital 
rubella can be reduced to a large extent. Moreover, 
this component can be deleted from the TORCH-
panel investigations, thereby reducing their cost.
Conclusions
Based on the findings of the study, it is concluded 
that a previous history of pregnancy wastage and 
the serological reactions for TORCH infections dur-
ing current pregnancy must be considered while 
managing BOH cases to reduce the adverse foetal 
outcome. Keeping consideration of the high cost 
of the test panel, selected tests (of the whole panel) 
are recommended on an individual case basis. In-
corporation of rubella immunization into the na-
tional immunization schedule is recommended. 
Toxoplasma-associated infection can be prevented   
by educating the public about avoidance of inges-
tion of raw or insufficiently-cooked meat and poul-
try and keeping proper hygiene. An extensive study 
covering a large population should be conducted 
to know the seropositivity of TORCH agents and 
also to know the real status of these infections in 
BOH cases.Kumari N et al.
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Table 1. Different presentations of BOH cases and matched controls with TORCH status
Case vs 
control
Age 
(years)
Parity Live- 
birth(s)
Abort-
ion(s)
Still-
birth(s)
Neonatal 
death(s)
TORCH 
status
Case
Control
24
26
1
2
0
2
1
0
0
0
1
0
All negative
T. gondii positive
Case
Control
22
21
1
2
0
2
1
0
1
0
0
0
Rubella virus posi-
tive
All negative
Case
Control
29
28
2
2
0
2
0
0
1
0
1
0
T. gondii, CMV, 
and HSV positive
All negative
Case
Control
23
25
2
2
0
2
0
0
0
0
2
0
Rubella virus posi-
tive
All negative
Case
Control
22
24
2
3
0
3
1
0
0
0
2
0
T. gondii and
rubella virus
positive
All negative
Case
Control
20
21
1
3
0
3
2
0
0
0
1
0
Rubella virus and 
HSV positive
All negative
Case
 
Control                                                               
18 
20
0 
2
0 
2
2 
0
0 
0
0 
0
T. gondii and 
rubella virus posi-
tive, HSV 
positive
All negative
Case
Control
24
25
1
2
0
2
1
0
1
 0
0
0
T. gondii positive
All negative
Case
Control
30
31
3
  3
0
3
0
0
0
0
3
0
Rubella virus 
positive
All negative
Case
Control
35
37
0
2
0
2
2
0
0
0
0
0
All negative
T. gondii positive
Case
Control
18
 
20
0
2
0
2
2
0
0
0
0
 
0
T. gondii positive 
and HSV positive
All negative
Case
Control
22
23
0
2
0
2
2
0
0
0
0
0
T. gondii positive
All negative
All=T. gondii, rubella, and HSV; BOH=Bad obstetric history; CMV=Cytomegalovirus; HSV=Herpes sim-
plex virus 2; T. gondii=Toxoplasma gondii; TORCH=Toxoplasma gondii, rubella virus, cytomegalovirus, 
and Herpes simplex virus
Table 2. Seropositivity of TORCH agents in the two groups
TORCH agent
Seropositivity in BOH group 
(n=12)
Seropositivity in control group
(n=12)
No.   %  No.   % 
Toxoplasma gondii 6 50 2 16.7
Rubella virus 6 50 0 0
Cytomegalovirus        1 8.3 0 0
Herpes simplex virus 2                4 33.3 0 0
BOH=Bad obstetric history; TORCH=Toxoplasma gondii, rubella virus, cytomegalovirus, and Herpes 
simplex virusKumari N et al. Screening of TORCH in women with bad obstetric history
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